Wall Street Zen Downgrades Edwards Lifesciences (NYSE:EW) to Buy

Key Points

• Edwards Lifesciences has been downgraded by Wall Street Zen from a "strong-buy" to a "buy" rating, reflecting a shift in analyst sentiment.
• Analysts maintain an average price target of $86.61 for the stock, with mixed ratings from various firms including a "hold" and multiple "buy" recommendations.
• In its latest earnings report, Edwards Lifesciences reported a 11.9% year-over-year revenue increase, achieving $1.53 billion in revenue and $0.67 EPS, surpassing estimates.

Edwards Lifesciences (NYSE:EW - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report released on Monday.

EW has been the subject of a number of other research reports. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a research report on Friday, July 25th. Stifel Nicolaus set a $85.00 target price on Edwards Lifesciences and gave the company a "buy" rating in a research note on Monday, September 22nd. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a report on Friday, July 25th. Finally, BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a report on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of "Moderate Buy" and an average price target of $86.61.

Edwards Lifesciences Price Performance

EW stock opened at $76.34 on Monday. The firm's fifty day moving average is $78.50 and its 200 day moving average is $75.78. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences has a 52 week low of $64.00 and a 52 week high of $83.00. The firm has a market cap of $44.82 billion, a P/E ratio of 10.98, a P/E/G ratio of 3.67 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company's stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.34% of the company's stock.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently added to or reduced their stakes in the company. Norges Bank bought a new position in Edwards Lifesciences in the 2nd quarter worth about $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company's stock worth $714,006,000 after purchasing an additional 4,805,819 shares during the last quarter. Nuveen LLC acquired a new position in shares of Edwards Lifesciences during the first quarter worth $330,881,000. Marshall Wace LLP lifted its holdings in shares of Edwards Lifesciences by 127.5% during the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company's stock valued at $539,303,000 after purchasing an additional 3,864,908 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after purchasing an additional 2,576,383 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.